Background: The large diversity of red blood cell antigens favors, especially in multi-transfused patients, the occurrence of autoimmunization and alloimmunization with the risk of hemolytic transfusion reactions. Thus, this study aimed to determine the rates of alloimmunization and autoimmunization in these individuals, as well as the types of alloantibodies and their systems, clinical and epidemiological aspects and the frequency of autoimmunity in alloimmunized and non-alloimmunized patients. Methods: In a retrospective study, 153 multi-transfused patients from 2006 to 2014 were evaluated. Sixty-eight had onco-hematological diseases, 64 had hemoglobinopathies and 21 had chronic renal failure. Descriptive analyses were carried out with th...
Alloimmunization is caused by exposure to erythrocytes from a donor who expresses antigens from blo...
Introduction: The development of alloantibodies is a major problem among thalassemia major individua...
Life-long red blood transfusion remains the main treatment for severe thalassemia. The development o...
Background: To determine the frequency and specificities of red blood cells -antibodies in multi-tra...
Background: Unexpected red blood cell alloantibodies can cause hemolytic transfusion reactions. In t...
Background: Blood transfusion usually results in production of alloantibody against one or more fore...
BACKGROUND: Autoantibodies (AUTO) to red blood cells (RBCs) are frequently associated with alloant...
Background: To study the frequency and specificity of various red cell alloantibodies in multi- tran...
Background: Alloimmunization is an adverse effect of blood transfusions. In Chile, alloimmunization ...
Background: It is well-known that alloimmunization to red blood cell antigens resulting from the gen...
<p>History of multiple transfusions in patients with hematological diseases increases the likelihood...
This study aimed at determining the presence and type of specific antibodies among multitransfused o...
BACKGROUND: Several irregular red blood cell alloantibodies, produced by alloimmunization of antigen...
Background: The aim is to detect the prevalence and specificity of red cell allo-antibodies underlyi...
Background: Thalassemia is a common hemoglobin disorder in Iran and one of the major public health ...
Alloimmunization is caused by exposure to erythrocytes from a donor who expresses antigens from blo...
Introduction: The development of alloantibodies is a major problem among thalassemia major individua...
Life-long red blood transfusion remains the main treatment for severe thalassemia. The development o...
Background: To determine the frequency and specificities of red blood cells -antibodies in multi-tra...
Background: Unexpected red blood cell alloantibodies can cause hemolytic transfusion reactions. In t...
Background: Blood transfusion usually results in production of alloantibody against one or more fore...
BACKGROUND: Autoantibodies (AUTO) to red blood cells (RBCs) are frequently associated with alloant...
Background: To study the frequency and specificity of various red cell alloantibodies in multi- tran...
Background: Alloimmunization is an adverse effect of blood transfusions. In Chile, alloimmunization ...
Background: It is well-known that alloimmunization to red blood cell antigens resulting from the gen...
<p>History of multiple transfusions in patients with hematological diseases increases the likelihood...
This study aimed at determining the presence and type of specific antibodies among multitransfused o...
BACKGROUND: Several irregular red blood cell alloantibodies, produced by alloimmunization of antigen...
Background: The aim is to detect the prevalence and specificity of red cell allo-antibodies underlyi...
Background: Thalassemia is a common hemoglobin disorder in Iran and one of the major public health ...
Alloimmunization is caused by exposure to erythrocytes from a donor who expresses antigens from blo...
Introduction: The development of alloantibodies is a major problem among thalassemia major individua...
Life-long red blood transfusion remains the main treatment for severe thalassemia. The development o...